4.7 Article

Qki is an essential regulator of microglial phagocytosis in demyelination

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 218, Issue 1, Pages -

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20190348

Keywords

-

Funding

  1. National Institutes of Health/National Cancer Institute under Cancer Center Support Grant [P30CA016672]
  2. National Multiple Sclerosis Society
  3. Cancer Prevention and Research Institute of Texas [RP120348, RP170002]
  4. National Cancer Institute [R37CA214800]
  5. American Cancer Society [RSG-17-029-01-CSM]
  6. Sontag Foundation
  7. Brockman Foundation
  8. MD Anderson Internal Research Grant
  9. National Institutes of Health [CA120813]

Ask authors/readers for more resources

This study demonstrates that Qki is an essential regulator of microglial phagocytic activity under demyelinating conditions. Depletion of Qki impairs myelin debris clearance, leading to compromised axon integrity and remyelination.
The mechanism underpinning the regulation of microglial phagocytosis in demyelinating diseases is unclear. Here, we showed that the Quaking protein (Qki) in microglia was greatly induced by demyelination in the brains of both mice and humans. Deletion of the Quaking gene (Qk) in microglia severely impaired the clearance of myelin debris. Transcriptomic profiling indicated that depletion of Qki impaired total RNA levels and splicing of the genes involved in phagosome formation and maturation. RNA immunoprecipitation (RIP) confirmed the physical interactions between the Qki protein and the mRNAs of Qki targets that are involved in phagocytosis, indicating that Qki regulates their RNA stability. Both Qki depletion and inhibition of Qki target Cd36 greatly reduced the phagocytic activity of microglia and macrophages. The defective uptake and degradation of myelin debris caused by Qki depletion in microglia resulted in unresolved myelin debris that impaired axon integrity, oligodendrocyte maturation, and subsequent remyelination. Thus, our results demonstrate that Qki is an essential regulator of microglia's phagocytic activity under demyelinating conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Genome-wide identification and differential analysis of translational initiation

Peng Zhang, Dandan He, Yi Xu, Jiakai Hou, Bih-Fang Pan, Yunfei Wang, Tao Liu, Christel M. Davis, Erik A. Ehli, Lin Tan, Feng Zhou, Jian Hu, Yonghao Yu, Xi Chen, Tuan M. Nguyen, Jeffrey M. Rosen, David H. Hawke, Zhe Ji, Yiwen Chen

NATURE COMMUNICATIONS (2017)

Article Biology

Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis

Xin Zhou, Seula Shin, Chenxi He, Qiang Zhang, Matthew N. Rasband, Jiangong Ren, Congxin Dai, Rocio Zorrilla-Veloz, Takashi Shingu, Liang Yuan, Yunfei Wang, Yiwen Chen, Fei Lan, Jian Hu

Summary: This study reveals the crucial role of Qki in controlling cholesterol biosynthesis in the central nervous system, which is essential for myelinogenesis. Depletion of Qki results in reduced cholesterol concentration in the brain, impairing proper myelin assembly.

ELIFE (2021)

Article Oncology

Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses

Andrew Fedoriw, Leilei Shi, Shane O'Brien, Kimberly N. Smitheman, Yunfei Wang, Jiakai Hou, Christian Sherk, Satyajit Rajapurkar, Jenny Laraio, Leila J. Williams, Chunyu Xu, Guangchun Han, Qin Feng, Mark T. Bedford, Linghua Wang, Olena Barbash, Ryan G. Kruger, Patrick Hwu, Helai P. Mohammad, Weiyi Peng

Summary: Protein arginine methyltransferases play crucial roles in cancer progression, with inhibition of type I PRMTs increasing T-cell infiltration and inducing durable anti-tumor responses in immunotherapy.

CANCER IMMUNOLOGY RESEARCH (2022)

Article Medicine, Research & Experimental

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade

Amber Hickman, Joost Koetsier, Trevin Kurtanich, Michael C. Nielsen, Glenn Winn, Yunfei Wang, Salah-Eddine Bentebibel, Leilei Shi, Simone Punt, Leila Williams, Cara Haymaker, Charles B. Chesson, Faisal Fa'ak, Ana L. Dominguez, Richard Jones, Isere Kuiatse, Amy R. Caivano, Sayadeth Khounlo, Navin D. Warier, Upendra Marathi, Robert Market, Ronald J. Biediger, John W. Craft, Patrick Hwu, Michael A. Davies, Darren G. Woodside, Peter Vanderslice, Adi Diab, Willem W. Overwijk, Yared Hailemichael

Summary: The small-molecule activator 7HP349 enhances the localization of tumor-specific T cells to tumors and improves antitumor response, with combinatorial treatment synergizing with neutrophils in inducing cancer regression.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available